ARS Pharmaceuticals, Inc. (SPRY)

5.62USD -0.88% (-0.05)

Over 6M: -37.9%

Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles and bars need the day’s open, high and low, and need room to be drawn in: past about a year of trading a body is thinner than a hairline, so those three offer the longest window that fits instead.

6 8 10
Mar Apr May Jun Jul Aug Sep

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '25 — Revenue: 32.5M Q3 '25 — Operating Cash Flow: -47M Q3 '25 — Net Income: -51.2M Q4 '25 — Revenue: 28.1M Q4 '25 — Operating Cash Flow: -43.5M Q4 '25 — Net Income: -41.3M Q1 '26 — Revenue: 22.7M Q1 '26 — Operating Cash Flow: -44.9M Q1 '26 — Net Income: -60.6M Q2 '26 — Revenue: 33.7M Q2 '26 — Operating Cash Flow: -60.9M Q2 '26 — Net Income: -62.3M -60M -40M -20M 0 20M 40M
Q3 '25 Q4 '25 Q1 '26 Q2 '26
Revenue Operating Cash Flow Net Income

How it scores

For a valuation multiple, the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.6
SBC / sales 26.7%
OE margin -194.9%
Oper. margin -185.0%
Accruals -7.6%
EBITDA margin -183.6%
FCF margin -168.1%
OCF margin -168.0%
Profit margin -184.2%
ROA -86.3%
ROCE -114.7%
ROE -1721.8%
Gross margin —
OCF / EBIT —
ROIC —

4 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

4.9
EV/Sales 4.4×
EV/OE -2.3×
P/C 3.9×
FCF yield -35.1%
P/B 44.7×
Div. yield —
EV/EBIT —
EV/GP —
Fwd P/E —
P/E —
PEG —

2 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.0
RPO / sales 0.0046×
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

6.8
ND/EBITDA 0.092
Interest cover -88.2×
Cash / Debt 1.5×
Debt payback 0.0 yr
Quick ratio 3.0×
Cash runway 0.24 yr
Debt / Eq 7.7×
F-score 3.4 pts
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

6.1
Sales CAGR 4Y +97.8%
Sales/sh Y/Y +8.1%
Sales Q/Q +114.2%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.